—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Madrigal Pharmaceuticals Inc (MDGL) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for MDGL, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 57/100 · S&P 500 fund at 71, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-09
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +5.0% over 20 sessions. Factor regime → 2026-10-12
  • Sector × region Health care in US: +2.8% week · +3.5% month · +6.2% quarter · +17.8% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-11
  • Sovereign pressure Index 0.04 · down 0.71 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-09
How it trades on rate days beta 0.18 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How MDGL has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.18 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Madrigal Pharmaceuticals Inc moved 0.18% on average · correlation 0.04 · higher than 18% of US names
  • Beta, last 3 months 0.56 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.87% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.04% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against MDGL on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Madrigal Pharmaceuticals Inc

MDGL in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Madrigal Pharmaceuticals is a biopharmaceutical company that develops treatments for metabolic dysfunction-associated steatohepatitis, a liver disease often called MASH. Its lead product, Rezdiffra, works by activating a thyroid hormone receptor in the liver to reduce fat build-up. The company is based in West Conshohocken, Pennsylvania, and was founded in 2016.
Where it sits in the stack
Madrigal carries no seat in Rubin or Halo, our indices for the AI build-out; it sits instead in the healthcare and biotechnology sleeve of the wider universe, outside the compute-and-chip chain the diary usually tracks.
Who it is priced against
No Closelooknet peer group is attached to this name; a comparator the market names on its own is Viking Therapeutics, another company working on MASH treatments.
Why Closelooknet tracks it
It carries a Closelooknet score, with momentum as its strongest reading; there is no index seat, no editions have quoted it, and its mention count in the diary stands at nil.
What the diary watches
The diary watches how sales of Rezdiffra develop and whether momentum in the shares holds up against the stock's distance from its recent high.

Madrigal Pharmaceuticals Inc (MDGL) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 39/100 composite (momentum 32, quality 22, valuation 13) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: initiation by Citigroup, 2026-09-23

The Street on this name

Analyst actions and the latest print for MDGL from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Initiation Citigroup — at Buy Initiated to Buy from Outperform 2026-09-23

1 action on the analyst wire since 2026-08-13: 1 initiation. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months

Dividends and capital return

What MDGL pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +5.5% in FY2025 98 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-13

Quick answers

What is Madrigal Pharmaceuticals Inc (MDGL)?

Madrigal Pharmaceuticals Inc trades as MDGL on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-13.

Is MDGL in a Closelooknet index?

Not currently — Madrigal Pharmaceuticals Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-13.

What is Madrigal Pharmaceuticals Inc's Closelooknet composite score?

39 out of 100, with momentum 32, quality 22 and valuation 13 sub-scores, as of 2026-10-13. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does MDGL trade against its moving averages?

Mixed moving-average stack: Trades -9.9% vs the 50-day and -8% vs the 200-day average, 24% below the 52-week high and +18.7% off the 52-week low. Computed from daily closes. As of 2026-10-12 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Madrigal Pharmaceuticals Inc compare with its peers?

Against its peer group (Biotechnology · US), Madrigal Pharmaceuticals Inc (MDGL) sits 24.0% below its 52-week high, 9.9% below its 50-day average; Halozyme Therapeutics Inc (HALO) is 4.9% below, BeiGene, Ltd. (ONC) is 9.0% below, argenx NV ADR (ARGX) is 24.3% below. Put any of them next to MDGL in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Madrigal Pharmaceuticals Inc trade when bond yields rise?

Over the past year Madrigal Pharmaceuticals Inc had a beta of 0.18 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 18% of US names. On the 10 sessions in which long bonds fell most it moved −0.87% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Madrigal Pharmaceuticals Inc do?

Madrigal Pharmaceuticals is a biopharmaceutical company that develops treatments for metabolic dysfunction-associated steatohepatitis, a liver disease often called MASH. Its lead product, Rezdiffra, works by activating a thyroid hormone receptor in the liver to reduce fat build-up. The company is based in West Conshohocken, Pennsylvania, and was founded in 2016. No Closelooknet peer group is attached to this name; a comparator the market names on its own is Viking Therapeutics, another company working on MASH treatments.

Where does Madrigal Pharmaceuticals Inc sit in the AI build-out?

Madrigal carries no seat in Rubin or Halo, our indices for the AI build-out; it sits instead in the healthcare and biotechnology sleeve of the wider universe, outside the compute-and-chip chain the diary usually tracks. It carries a Closelooknet score, with momentum as its strongest reading; there is no index seat, no editions have quoted it, and its mention count in the diary stands at nil.

Does Madrigal Pharmaceuticals Inc pay a dividend?

No cash distribution shows in Madrigal Pharmaceuticals Inc’s price series over the last three years. The share count rose 5.5% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Madrigal Pharmaceuticals Inc recently?

The most recent analyst action on Madrigal Pharmaceuticals Inc on the Closelooknet wire is a initiation by Citigroup on 2026-09-23 (at Buy). 1 action on the analyst wire since 2026-08-13: 1 initiation. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for MDGL, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.